CARTER ROBERT B 4

What Happened
Robert B. Carter, a director of Quest Diagnostics (DGX), acquired 6 shares on January 28, 2026 at $183.51 per share, for a total value of about $1,101. This was an acquisition (purchase) made through a dividend reinvestment plan rather than an open-market buy.

Key Details

• Transaction date: 2026-01-28; Price: $183.51; Shares acquired: 6; Total ≈ $1,101.
• Filing date (Form 4): 2026-02-20; transaction marked with timeliness code "L".
• Footnote: These shares were acquired via a dividend reinvestment plan administered by the reporting person's broker and are eligible for deferred reporting on Form 5 under Rule 16a-6; the insider chose to report the transaction early on this Form 4.
• Shares owned after the transaction: not specified in the information provided.
• No indication of option exercise, gift, tax withholding, or a 10b5-1 plan in this filing.

Context
Dividend reinvestment transactions are routine and often small; while purchases can be viewed positively, this small automatic reinvestment is generally not a strong standalone signal about insider sentiment. The "L" code here relates to the rule permitting deferred reporting for broker-administered DRIP purchases, and the reporting person elected to disclose it on Form 4.